ment; neoadjuvant chemotherapy
In Western countries, about 50% of gastric cancers are diagnosed at a far advanced stage when complete curative resection (R0) is impossible due to local organ infiltration and/or additional metastatic sites. 1 These patients are offered palliative chemotherapy regimens. Achievable response rates in second-generation combinations within randomized trials are about 40% at a median survival of 6-10 months. [2] [3] [4] The subgroup of locally advanced irresectable tumors can be considered for preoperative chemotherapy. Multiple phase II studies have shown an increased rate of R0 resections and a median survival of 16-43 months. [5] [6] [7] [8] [9] [10] [11] Ongoing randomized trials are attempting to confirm these promising results from phase II studies. In the present study, we enrolled patients with metastatic or locally far-advanced irresectable tumors on a multimodality treatment approach including dose-intensive chemotherapy and surgery. The aim of our study was to investigate whether it is possible to achieve (1) a high response rate, (2) local R0 resectability despite histologically proven peritoneal carcinomatosis or far advanced local tumor and (3) whether preoperative chemotherapy may control irresectable metastatic tumor sites to prolong survival after local R0 resection.
In this study, we report a high rate of tumor control and local R0 resectability after high-dose chemotherapy (HD-CT) and autologous peripheral blood stem cell transplantation (aPBSCT) prior to gastrectomy.
Patients and methods

Patient selection
The local ethical committee approved the protocol. Patients provided their written informed consent before enrolling in the study. Additional written informed consent was obtained prior to surgery.
Consecutive patients with a locally advanced irresectable tumor with direct organ infiltration or metastatic bidimensionally measurable disease were eligible. Further inclusion criteria comprised absence of previous chemotherapy, radiotherapy and gastric resection. Additional criteria were as follows: age 418 and o65 years, histologically proven adenocarcinoma of the stomach, World Health Organization (WHO) performance status p3, adequate baseline organ function, defined as WBC count X3000 cells/ml. Patients who had significant comorbid conditions were excluded from this study. ) was transplanted on day 0. Patients who achieved a 450% size reduction of the target lesion following the first cycle of MitPEB qualified for an identical second cycle 4 weeks later. Adequate hydration and alkalinization of the urine was achieved before the application of cisplatin and continued until 24 h after the end of induction or conditioning chemotherapy. Following EAP, patients received ciprofloxacin 750 mg twice a day. Amphotericin p.o. was added during MitPEB cycles until hematopoietic recovery occurred.
Pretreatment evaluation and follow-up
Baseline evaluation included physical examination, complete blood cell count (CBCC), serum chemistry including electrolytes, liver, renal and lung function tests, ECG, radionuclid ventriculography, chest X-ray, abdominal ultrasound, computed tomographic (CT) scans of the brain, thorax and abdomen, bone scan, endoscopy with biopsies and endosonographic ultrasound (EUS), bone marrow aspiration for cytology and laparoscopy with peritoneal lavage or histology. During the treatment period, patients were monitored before each cycle and at the end of chemotherapy, which included assessment of toxicities, CBCC, serum chemistry and physical examination. Assessment of the target lesions by CT scan, abdominal ultrasound, and endoscopy, and EUS was performed after every chemotherapy course. Prior to surgery liver, kidney and pulmonary functions were evaluated.
Resectability was assessed in patients achieving partial remission or 450% size reduction of the target lesion. Gastrectomy and D2-lymph node dissection was performed within 8 weeks after the last cycle of chemotherapy. Gastrectomies were extended as required to achieve local R0 -resection status, if possible.
During the postsurgical follow-up period, patients were evaluated every 3 months for performance status, toxicities and response (measuring of target lesions) until disease progression. At progression, a systematic evaluation of the metastatic sites was performed by ultrasound and chest Xray.
Patient selection for surgery
Patients achieving partial response to preoperative tandem HD-CT or 450% reduction of the target lesion after MitPEB 2 were selected for surgery according to the following criteria: (1) organ functions according to the baseline criteria, (2) no evidence of extra-abdominal metastatic disease and clinical control of peritoneal carcinomatosis (disappearance of ascites and/or peritoneal tumors), (3) residual abdominal metastases (450% reduction of the target lesion) and clinical control of peritoneal carcinomatosis, (4) residual abdominal disease (450% reduction of the target lesion) and no initial peritoneal carcinomatosis.
Of note, residual abdominal metastases, independent of their localization and resectability, were no contraindication for surgery. Laparoscopic evaluation was not repeated prior to surgery. Palliative resections were performed in patients with stenosis symptoms, irrespective of tumor reduction following chemotherapy.
Patients eligible for local R0 resection according to the above-mentioned criteria were hospitalized throughout the restaging procedure. All patients underwent pulmonary training and oral supplementation prior to surgery. The operative procedure was carried out via an abdominal midline incision. Patients received inhalation anesthesia with isofluran. Cefotaxim 3 Â 1.5 g and metronidazole 3 Â 0.5 g were administered as perioperative antibiotics.
Toxicity and response evaluation
All toxicities were graded according to WHO criteria. Tumor response was assessed prior to the scheduled new cycle of chemotherapy, before and after surgery. Complete remission (CR), partial remission (PR), no change (NC) or progressive disease (PD) were defined according to WHO response definitions. Tumor responses were confirmed following the second cycle of MitPEB, prior to surgery and after surgery. In patients proceeding to surgery after one cycle of HD-CT (n ¼ 2), tumor response was confirmed after tumor resection.
Histopathologic evaluation
Laparoscopy with biopsies and lavage was mandatory for patients without cytologically proven malignant ascites. For initial diagnosis and for restaging after the last chemotherapy, multiple biopsies were taken from the primary tumor at gastroscopy. Histologic tumor regression was evaluated in the resected specimen as described by Yonemura et al 12 grade 0, no histologic manifestation of chemotherapy; grade 1, degeneration plus necrosis of tumor cells in 1/3 to 2/3 of the microscopic field; grade 2 single tumor cells in less than 1/3 of the microscopic field, degeneration plus necrosis; grade 3, no residual tumor cells. In non resected patients, biopsies of the primary tumor site following the last chemotherapy were used to define tumor regression.
Data analysis and statistics
The primary end point of the present study was response to treatment and tolerability of the complete treatment concept. Secondary end points were rate of local R0 resectability, progression-free (PFS) and overall survival (OS). Measurable metastatic lesions (CT scan) were used for response evaluation. Primary tumors were considered as nonmeasurable lesions despite the routinely perfomed evaluation by EUS. Comparison of different subgroups within the treatment arm was performed using the log-rank test. The safety analysis was restricted to patients receiving at least one cycle of HD-CT. Survival was estimated using the method of Kaplan and Meier.
OS was defined as the time interval between the start of chemotherapy and the time of disease progression or death. Duration of response was defined as the time interval between the begin of chemotherapy and date of disease progression for responders only. If the event was not yet observed at the time of last record, the patient was censored at that time point.
The following variables were used for univariate analysis to evaluate OS and PFS: age at diagnosis, sex, metastatic stage, tumor localization, R0 resectability, response to preoperative chemotherapy, changes in T stage, histology and histologic regression. Fisher's exact test and Student's t-test were used to identify significant associations between clinical and biological variables. Relative risk of progression or death was calculated by univariate analyses using Cox regression.
The above-mentioned variables could not be used to create multiple regression models to evaluate OS or PFS because only ECOG performance status achieved prognostic significance as pretherapeutic parameter.
Results
From October 1996 to March 2000, 26 patients with metastatic gastric cancer (n ¼ 25) from a single institution were enrolled on our multimodal treatment approach.
Patient characteristics are listed in Table 1 . All patients had bidimensionally measurable lesions. More than one metastatic site (2-4 sites) was assessable in 14 patients (54%). Peritoneal carcinomatosis had been histologically or cytologically confirmed in 18 cases (12 laparoscopies). One patient had no metastatic site but an irresectable uT4 tumor with infiltration of the pancreas, and seven patients had extra-abdominal disease. None of the 26 patients was resectable with R0 intention. The reasons for irresectability were direct infiltration per continuitatem (uT4, 77%) and/or peritoneal carcinomatosis (69%).
Safety and toxicity
All 26 patients received at least one cycle of HD-CT (MitPEB) following induction and mobilization with EAP. Six patients did not qualify for a second cycle of MitPEB because of less than 50% size reduction of the target lesion. One patient in PR after MitPEB 1 suffered from reactivation of hepatitis C, and another presented with a new hypodense hepatic lesion on CT scan after MitPEB 1. Both patients progressed directly to surgery. Histology of the resected liver lesion showed tumor necrosis. At diagnosis, three patients presented with intestinal bleeding from the primary tumor site. The bleeding stopped during induction treatment. One patient suffered from a severe paraneoplastic Bazex acrokeratosis, which completely resolved 5 months after start of chemotherapy. This patient is still in CR.
As demonstrated in Table 2 the modified EAP schedule was well tolerated in combination with G-CSF and antibiotic prophylaxis. Hematotoxicity was frequently observed, whereas nonhematologic toxicities were mild. Four patients (15%) were hospitalized due to infections during neutropenia.
The major toxicity of the MitPEB schedule was pancytopenia with severe neutropenia (WBC o0.5 Â 10 9 /l). A total of 23% and 18% of the patients, respectively, suffered from grade 3 infections (pneumonia, urinary tract infection, fever of unknown origin). The median duration was 5.1 days (range 4-8 days). Time from transplantation (Table 2) . Grade 3 nonhematologic toxicities were only observed in patients with ascites or ECOG performance status grade 3. Therefore, no further dose escalation within the MitPEB regimen was undertaken and the doses used initially were defined as the maximum feasible dose. No patient discontinued the study treatment because of toxicity.
Response
Response to preoperative HD-CT is shown in detail in Table 3 . A total of 20 patients (77%) achieved a 450% reduction of the target lesion after the first cycle of MitPEB. Further tumor regression was observed in 14 of the 18 patients (78%) receiving a second cycle of HD-CT. Two patients had no evidence of metastatic disease after tandem HD-CT.
Gastrectomy and D2 lymph node dissection with insertion of a feeding jejunostomy was carried out in all 14 patients 5-7 weeks after HD-CT. In 11 of these patients, gastrectomy was extended by resection of additional tumor-bearing sites according to the oncological demands to achieve R0. Response after surgery is shown in Table 5 .
Surgical technique was not altered in any of the patients receiving HD-CT. No scar formation was noted during operation at former tumor-bearing sites. Nevertheless, tissue appeared to be more adhesive to vascular structures on D2 lymph node dissection resulting in more difficult tissue preparation. However, this did not promote technical complications.
Enteral nutrition was established on day 2 after surgery until 1000 kcal/ day could be infused. Oral food intake was built up on day 5, after radiological proof of absence of an anastomotic leakage. Four out of 14 (28%) patients suffered from surgical complications. Half of the patients who had had surgery experienced infectious problems including pneumonia and urinary tract infections (Table 4 ). These rates were higher than for a reference group which suffered 3.5% surgical problems and infectious complications, respectively. However, all infectious complications were successfully treated with standard antibiotics and did not result in a longer hospital stay, compared with patients who did not receive preoperative chemotherapy (data not shown).
In 12 of 14 selected patients (86%), local R0 resection was achieved. Two patients had R1 resection due to retroperitoneal perineural tumor infiltration. Residual tumor or tumor cells were found in all resected specimens. Peritoneal carcinomatosis (n ¼ 8) histologically resolved in seven patients selected for surgery (87%). All resected specimens (n ¼ 15, 58%), and all tumor control biopsies (primary tumor site), taken after the last cycle of HD-CT (10 nonresected patients, 38%) were evaluated for degree of histologic tumor regression (Table 5) . Histology revealed major tumor regression (grade 3) in seven patients with local R0 resection. In contrast, within the patients achieving PR but not being selected for surgery, no, or less, tumor regression (grade 0-1) was found in five cases and grade 2 regression in one case.
For T staging, all 26 patients received EUS investigation, 14 patients were revaluated by EUS before gastric resection ( Table 5 ). In 10 of 14 patients, a T down staging was observed, two T steps in six patients, in four patients one T step and the initial uT4 was found in three patients ( Table 7) . Histology of the resected specimen confirmed the EUS-T stage in seven cases; in four cases the down staging was overestimated, and underestimated in one case. Thus, sensitivity of EUS to predict the pathologic T stage was low (53%).
Survival
Median PFS and OS are shown in Table 6 . The median follow-up was 3.2 years. No patient was lost to follow-up. All deaths were cancer-related.
On univariate analysis, ECOG performance status grade 0 and 1 vs grade 2 and 3 was the only tumor-associated variable with significant impact on PFS and OS (Table 6 ). All other variables were not predictive for outcome, probably due to the small number of patients enrolled. The number of metastatic sites at diagnosis did not influence postoperative survival. T stage (uT3 vs uT4) and cN stage also had no influence on outcome.
In contrast, all treatment-related response parameters had a significant impact on OS and PFS (Table 7) . Strong histologic tumor regression following preoperative tandem HD-CT was the parameter with the highest predictivity for improved PFS and OS (Figure 1 ). T down staging was only associated with significantly improved PFS, but not OS.
Discussion
Our study demonstrates that the multimodal treatment approach is feasible with acceptable toxicity and opens a new therapeutic window in patients with far advanced gastric cancer.
Based on the promising response rates from 30 to 60% in patients with advanced gastric cancer treated in phase II trials on second-generation protocols, [13] [14] [15] [16] we generated a dose-intensive tandem HD-CT regimen combined with aPBSCT. This protocol achieved a tumor response rate of 77%, resectability of the primary tumor in 46% of all patients and long-term control of metastatic tumor sites.
Moreover, similar to results obtained from studies applying preoperative CT in non-metastatic, but irresectable cases, R0 resectability remains a favorable prognostic Table 5 Response evaluation after surgery parameter. 6, 8, 10, [17] [18] [19] [20] Despite these promising results, the OS could not be improved in comparison to results from studies administering conventional CT in metastatic gastric cancer. [2] [3] [4] The reasons for this could be as follows: (1) the present study selected far advanced disease as reflected by a rate of 65% patients with ECOG status 2 and 3. The frequency of poor ECOG status in studies investigating palliative CT (10-15%) is much lower. 4 Poor ECOG status was the only unfavorable prognostic parameter at diagnosis in the present study. (2) The treatment-related morbidity in patients with poor ECOG status was increased. Additional insufficient tumor control in this group might also be a reason for poor survival rates.
Nevertheless, the study shows for the first time that patients with marked histologic tumor regression in the resected specimen may significantly benefit from the multimodal treatment approach (Figure 1) .
The study also addresses the specific problems of response evaluation in metastatic gastric cancer: firstly, poor results were obtained from EUS to demonstrate T down staging. 22 Secondly, evaluation of tumor response at metastatic sites by CT scanning was insufficient.
According to WHO criteria, no patient achieved CR prior to surgery. However, postoperative histologic analysis of tumor regression in the resected specimens revealed no evidence of disease in seven of 26 cases (27%). On followup, tumor shrinkage was documented in nonresected liver lesions. Additional imaging techniques should be included in future.
In this multimodal treatment approach, surgery was introduced to prove histologic response, and most importantly to improve survival in responders. Indication for gastrectomy was solely based on the criteria outlined, offering a high chance of achieving local R0 resection. Indeed, we do not know whether surgery following preoperative CT really does improve survival in advanced gastric cancer, but the study design followed other successful multimodal approaches in other metastatic tumor types. [23] [24] [25] Therefore, it is likely that patients with metastatic gastric cancer who respond may benefit from such an approach. This is supported at least in part by the favorable prognostic impact of R0 resectability (Table 7) and long-term survival of some patients (Figure 1) .
Preoperative CT has not even been established in irresectable nonmetastatic gastric cancer, despite promising results. [18] [19] [20] [21] Therefore, retrospective studies are ongoing to define the potential chemosensitivity on a molecularpathologic basis from biopsies of the primary tumor site. From our results, patient selection for a multimodal treatment approach should be based on (1) favorable ECOG status and (2) non-extra-abdominal metastatic disease.
Until now no selection criteria have been available for optimizing dose intensity or drug combination of the preoperative CT. Within the present study, a high PR rate (77%) is associated with tumor regression grade 3 in only 27% of the cases. It seems likely that regression grade 3 could also be observed following conventional CT with third-generation protocols. Long-term survival with stage IV gastric cancer treated with surgery or chemotherapy alone is possible in rare cases. 4, 18 A study randomizing preoperative HD-CT vs conventional CT is still ongoing. 
